Acyl-Coenzyme A Binding Protein (ACBP) levels paradoxically increase post-bariatric surgery, questioning its obesity biomarker role.
Background
Circulating acyl-coenzyme A binding protein/diazepam binding inhibitor (ACBP/DBI) is a potent appetite stimulator implicated in obesity pathogenesis. It promotes hepatic and adipose glucose uptake, inhibits fatty acid oxidation, activates orexigenic neurons, and increases food intake. Elevated plasma ACBP levels are observed in obese individuals and correlate with metabolic dysfunction-associated steatotic liver disease (MASLD) severity, suggesting a pathological feedforward loop where liver and adipose tissue produce ACBP, altering their metabolic state. This established understanding positions ACBP as a key player in metabolic dysfunction.
Study Design
A recent study by Meyer et al. (2025), highlighted in The Biomolecules Journal Club, investigated the changes in circulating ACBP levels following bariatric surgery in morbidly obese patients. The study measured plasma ACBP concentrations and assessed ACBP transcript levels in both hepatic and adipose tissues post-surgery. The primary objective was to determine if weight loss induced by bariatric surgery would lead to the anticipated decrease in ACBP, consistent with its proposed role as an obesity inducer and biomarker. This design aimed to critically reflect on the prevailing concept of ACBP's metabolic regulation.
Results
Contrary to expectations, Meyer et al. (2025) found that weight loss achieved through bariatric surgery in morbidly obese patients was associated with an increase in plasma ACBP concentrations, rather than the anticipated decrease. This unexpected finding challenges the established view of ACBP as a straightforward obesity biomarker that should decline with successful weight reduction. Furthermore, the study reported that bariatric surgery did not significantly alter ACBP transcript levels in either the hepatic or adipose tissues. This suggests that the observed increase in circulating ACBP might not originate from changes in gene expression within these traditionally implicated tissues. The lack of change in tissue-specific ACBP mRNA levels, coupled with rising plasma levels, indicates a potential disconnect in the presumed primary sources of circulating ACBP. > The most striking finding was the paradoxical increase in plasma ACBP levels following bariatric surgery-induced weight loss, directly contradicting its expected role in obesity.
Why It Matters
This finding necessitates a critical re-evaluation of ACBP's role in obesity and metabolic dysfunction. If ACBP levels rise post-bariatric surgery despite significant weight loss, its utility as a simple biomarker for obesity severity or treatment efficacy becomes questionable. Understanding the true primary source and regulatory mechanisms of circulating ACBP is now paramount. This research suggests that current models of ACBP production and its impact on metabolic tissues may be incomplete. For peptide users and researchers, this highlights the complexity of metabolic pathways and the need for deeper mechanistic insights beyond simple correlations. Future studies must selectively eliminate ACBP expression from specific cell types (e.g., hepatocytes, adipocytes) to precisely quantify their contribution to circulating levels, potentially leading to new therapeutic targets or diagnostic approaches for metabolic diseases.
